Perrigo Q3 Earnings Call Highlights
Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered guidance are likely to depress the stock in the near term, though the divestiture proceeds could support longer‑term fundamentals.
Market read
First‑report earnings and guidance for a mid‑cap consumer health company, providing fresh data for traders.
What to watch
Cost‑saving initiatives and the infant formula divestiture may improve margins over the longer term.
Background
Perrigo (NYSE:PRGO) is a global consumer self‑care company. The article summarizes its Q3 earnings call and forward outlook.
Ticker impact
Q3 earnings release shows lower sales, margin compression and guidance indicating a decline in core net sales and earnings for 2026.
likely downside as market prices in lower sales and earnings guidance
Revenue and EPS both fell YoY, margins contracted, and guidance projects a decline, which typically triggers a sell-off.
Market effects
Self‑care and OTC health sector may see broader pressure as Perrigo signals weaker demand.
U.S. consumer health stocks could face short‑term weakness.
European OTC brands may also feel sentiment drag due to Perrigo's outlook.
Counterpoint
If inventory build‑up improves in Q4, the guidance could be revised upward, offering a buying opportunity.
Key entities
- ExecutiveEduardo Bezerra
Chief Financial Officer who presented the earnings results.
- ExecutiveManzone
Company spokesperson discussing inventory trends and divestiture benefits.
